| T28374 |
PF-06651481-00
|
1391063-17-4
|
98%
|
|
|
PF-06651481-00 (Bosutinib Isomer I) is a Bosutinib analog and a Bcr-Abl inhibitor.
|
| T72958 |
BCR-ABL-IN-7
|
688050-42-2
|
98%
|
|
|
BCR-ABL-IN-7 is a WT and T315I mutant ABL kinase inhibitor.BCR-ABL-IN-7 potently inhibits WT and T315I mutant ABL kinase activity.BCR-ABL-IN-7 can be used in chr...
|
| T4320 |
Flumatinib
|
895519-90-1
|
98%
|
|
|
Flumatinib (HHGV678) is an orally bioavailable tyrosine kinase inhibitor flumatinib, with potential antineoplastic activity.
|
| T4618 |
BGG463
|
890129-26-7
|
|
|
|
BGG463 (K 0859) can inhibit c-ABL-T334I, BCR-ABL and BCR-ABL-T315I variants with a 50% inhibitory concentration (IC50) of 0.25 μM, 0.09 μM and 0.590 μM, respecti...
|
| T7186 |
CZC-8004
|
916603-07-1
|
|
|
|
CZC-8004 (CZC-00008004) is a pan-kinase(ABL kinase) inhibitor and binds a range of tyrosine kinases.
|
| T8488 |
GMB-475
|
2490599-18-1
|
|
|
|
GMB-475 is a BCR-ABL1 tyrosine kinase degrader based on PROTAC, overcoming BCR-ABL1-dependent drug resistance. GMB-475 targets BCR-ABL1 protein and recruits the ...
|
| T16545 |
Pivanex
|
122110-53-6
|
|
|
|
Pivanex (Pivalyloxymethyl butyrate) is an orally active HDAC inhibitor and an antimetastatic and antiangiogenic agent. Pivanex downregulates the Bcr-Abl protein ...
|
| T2116 |
AEE788
|
497839-62-0
|
|
|
|
AEE788 (NVP-AEE 788) has been used in trials studying the treatment of Cancer, Glioblastoma Multiforme, and Brain and Central Nervous System Tumors.
|
| T22378 |
Nilotinib hydrochloride
|
923288-95-3
|
100%
|
|
|
Nilotinib hydrochloride(AMN-107 HCl) is an orally available Bcr-Abl tyrosine kinase inhibitor with antitumor activity for modulation of neuroinflammation and cog...
|
| T3196 |
GNF-7
|
839706-07-9
|
97.05%
|
|
|
GNF-7 is Bcr-Abl WT and Bcr-Abl T315I inhibitor with IC50 of 133 nM and 61 nM, respectively.
|
| T67847 |
Imatinib impurities3
|
404844-11-7
|
97.05%
|
|
|
Imatinib impurities3 is a protein kinases inhibitor with IC50 values of 6.95uM, 0.245uM, 0.139uM for ABL1 wt, KIT wt, PDGFRR wt, respectively.
|
| T22553 |
Adaphostin
|
241127-58-2
|
97.31%
|
|
|
Adaphostin (NSC-680410) is a p210Bcr/Abl tyrosine kinase inhibitor with IC50 of 14 μM.
|
| T16750 |
Rigosertib
|
592542-59-1
|
97.33%
|
|
|
Rigosertib (ON-01910) is a selective and non-ATP-competitive inhibitor of PLK1 (IC50: 9 nM). Rigosertib is a multi-kinase inhibitor and a selective anti-cancer a...
|
| T6348 |
NVP-BHG712
|
940310-85-0
|
97.96%
|
|
|
NVP-BHG712 is a specific EphB4 inhibitor with ED50 of 25 nM that discriminates between VEGFR and EphB4 inhibition; also shows activity against c-Raf, c-Src and c...
|
| T1817 |
GNF-2
|
778270-11-4
|
98%
|
|
|
GNF-2 is a highly selective non-ATP competitive inhibitor of Bcr-Abl.
|
| T26625 |
AN-019
|
879507-25-2
|
98.01%
|
|
|
AN-019 (NRC-019) is a Bcr-Abl kinase inhibitor with antitumor activity for the study of chronic myelogenous leukemia (CML) and breast cancer.
|
| T3641 |
NVP-BAW2881
|
861875-60-7
|
98.07%
|
|
|
NVP-BAW2881 (BAW2881) is a potent and selective VEGFR inhibitor (vascular endothelial growth factor receptor tyrosine kinase inhibitor) with activity to inhibit ...
|
| T4053 |
AST 487
|
630124-46-8
|
98.17%
|
|
|
AST 487 (NVP-AST 487) is a RET kinase inhibitor, inhibiting RET autophosphorylation and activation of downstream effectors. It also can inhibit Flt-3.
|
| T30855 |
CGP77675
|
234772-64-6
|
98.23%
|
|
|
CGP77675 (ZINC1488120) is a potent and selective inhibitor of Src family kinase with IC50s of 5-20 and 40 nM for the phosphorylation of peptide substrates and au...
|
| T22552L |
AD57
|
1093380-42-7
|
98.23%
|
|
|
AD57 is a potent inhibitor of both c-Src and Abl with IC50 of 0.025 μM and 0.041 μM, respectively.
|
